Disease · MONDO_0005364

Graves disease

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. Graves disease. Diseases, record MONDO_0005364. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005364

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: Graves disease; Open Targets
Open Targets ID: MONDO_0005364; Open Targets
Other names: Basedow disease, Basedow's disease, Flajani-Basedow-Graves disease, exophthalmic goiter, toxic diffuse goiter; Open Targets
Disease Ontology: DOID:12361; Disease Ontology
MeSH: D006111; MeSH
NCI Thesaurus: C3071; NCI Thesaurus
Highest stage of its drugs: Approval, for 2 of its 24 drugs, from TTD; Open Targets

Drugs24

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
IPODATE	CHEMBL1201243	Small molecule	Approval	TTD	1	0	0	Drugs and targets
TEPROTUMUMAB	CHEMBL1743079	Antibody	Approval	TTD	1	0	0	Drugs and targets
METHIMAZOLE	CHEMBL1515	Small molecule	Phase 3	ClinicalTrials.gov	13	13	13	Drugs and targets
POTASSIUM IODIDE	CHEMBL1141	Small molecule	Phase 3	ClinicalTrials.gov	4	4	3	Drugs and targets
PROPYLTHIOURACIL	CHEMBL1518	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
CHOLESTYRAMINE	CHEMBL1201625		Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
EFGARTIGIMOD ALFA	CHEMBL4297551	Protein	Phase 3	ClinicalTrials.gov	2	2	1	Drugs and targets
CARBIMAZOLE	CHEMBL508102	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
IODINE	CHEMBL1201225	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
PREDNISOLONE	CHEMBL131	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 24

See all 24 drugs

Targets12

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	3	Glucocorticoid receptor agonist	Phase 3	https://conductscience.org/library/genes/2908	Drugs and targets
TPO	Thyroid peroxidase	3	Thyroid peroxidase inhibitor	Phase 3	https://conductscience.org/library/genes/7173	Drugs and targets
FCGRT	IgG receptor FcRn large subunit p51	2	IgG receptor FcRn large subunit p51 antagonist; IgG receptor FcRn large subunit p51 inhibitor	Phase 3	https://conductscience.org/library/genes/2217	Drugs and targets
MS4A1	B-lymphocyte antigen CD20	2	B-lymphocyte antigen CD20 binding agent	Phase 1/2	https://conductscience.org/library/genes/931	Drugs and targets
VDR	Vitamin D3 receptor	2	Vitamin D receptor agonist	Phase 2	https://conductscience.org/library/genes/7421	Drugs and targets
BTK	Tyrosine-protein kinase BTK	1	Tyrosine-protein kinase BTK inhibitor	Phase 2	https://conductscience.org/library/genes/695	Drugs and targets
CD40	Tumor necrosis factor receptor superfamily member 5	1	Tumor necrosis factor receptor superfamily member 5 inhibitor	Phase 2	https://conductscience.org/library/genes/958	Drugs and targets
DIO1	Type I iodothyronine deiodinase	1	Type I iodothyronine deiodinase (Type-I 5'-deiodinase) (DIOI) (Type 1 DI) (5DI) inhibitor	Phase 3	https://conductscience.org/library/genes/1733	Drugs and targets
FKBP1A	Peptidyl-prolyl cis-trans isomerase FKBP1A	1	FK506-binding protein 1A inhibitor	Phase 2	https://conductscience.org/library/genes/2280	Drugs and targets
IGF1R	Insulin-like growth factor 1 receptor	1	Insulin-like growth factor I receptor antagonist	Approval	https://conductscience.org/library/genes/3480	Drugs and targets

1 to 10 of 12

See all 12 targets

Trials30

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 3 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT04080505	Does Potassium Iodide (SSKI) Reduce Vascularity in Graves' Thyroidectomy?	Phase 3	29	2024-09-19	Graves Disease	POTASSIUM IODIDE	Its record names the disease	ClinicalTrials.gov
NCT02993302	Effects Of Oral Alfacalcidol On Maturation Of Dendritic Cells In Graves' Disease Patients	Phase 2	25	2020-02-20	Graves Disease	ALFACALCIDOL	Its record names the disease	ClinicalTrials.gov
NCT01269749	Radioactive Iodide Therapy for Pediatric Graves' Disease	Phase 2	19	2017-11-06	Graves' Disease	IODIDE	Its record names the disease	ClinicalTrials.gov
NCT02713256	A Study to Evaluate the Safety and Effect of CFZ533 on Patients With Graves' Disease	Phase 2	15	2018-05-21	Graves' Disease	ISCALIMAB	Its record names the disease	ClinicalTrials.gov
NCT05043233	Observation in the Treatment of Graves' Disease		1,000		Patient Acceptance of Health Care	METHIMAZOLE	Its record names the disease	ClinicalTrials.gov
NCT07040306	A Clinical Follow-up Study on Drug Therapy for Graves' Disease Patients in China		1,000		Graves´ Disease	METHIMAZOLE	Its record names the disease	ClinicalTrials.gov
NCT04686006	Effective Iodide Therapy for Untreated Patients With Graves' Hyperthyroidism Avoiding Thionamide Drugs With Many Side Effects		504		Graves Disease	POTASSIUM IODIDE	Its record names the disease	ClinicalTrials.gov
NCT02376088	Characteristics of Islet β-cell Functions in Chinese Patients With Graves' Disease		328		Graves Disease	METHIMAZOLE	Its record names the disease	ClinicalTrials.gov
NCT07596849	A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease.	Phase 3	230		Graves Disease	EFGARTIGIMOD ALFA	Its record names the disease	ClinicalTrials.gov
NCT06068179	Graves' Disease Remission Study: MycoMeth Combo	Phase 2/3	205		Graves' Disease	METHIMAZOLE, MYCOPHENOLATE MOFETIL	Its record names the disease	ClinicalTrials.gov

1 to 10 of 30

See all 30 trials

Comparisons in its trials6

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
SSKI (Potassium Iodide) vs No SSKI: deaths from any cause	0 of 16	0 of 11	27	NCT04080505	Trial comparisons
SSKI (Potassium Iodide) vs No SSKI: serious adverse events	0 of 16	0 of 11	27	NCT04080505	Trial comparisons
PTU + Oral 1α-D3 vs PTU + Placebos: deaths from any cause	0 of 13	0 of 12	25	NCT02993302	Trial comparisons
PTU + Oral 1α-D3 vs PTU + Placebos: serious adverse events	0 of 13	0 of 12	25	NCT02993302	Trial comparisons
RAI Treatment vs ATD Group: deaths from any cause	0 of 16	0 of 3	19	NCT01269749	Trial comparisons
RAI Treatment vs ATD Group: serious adverse events	0 of 16	0 of 3	19	NCT01269749	Trial comparisons

Papers from its trials30

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
36479875	RESULT	1	PubMed
36346684	RESULT	1	PubMed
35959915	RESULT	1	PubMed
35604323	RESULT	1	PubMed
35223896	RESULT	1	PubMed
34598995	RESULT	1	PubMed
33574798	RESULT	1	PubMed
32929476	RESULT	1	PubMed
32616746	RESULT	1	PubMed
32055040	RESULT	1	PubMed

1 to 10 of 30

See all 30 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005364

GET https://conductscience.org/api/diseases/v1/MONDO_0005364/drugs?page=2

API reference For AI assistants